Comparison of α-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: Assessment of changes in DAT binding with [ 123I]IPT SPECT

Journal of Neural Transmission

Volumn 111, Issue 8, 2004, Pages 1041-1052

  Popperl G ^a,f   Tatsch, K ^a   Ruzicka, E ^b   Storch, A ^c   Gasser, T ^d   Schwarz, J ^e  

^a UNIVERSITY OF MUNICH   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

dihydroergocryptine; 123I IPT SPECT; Levodopa; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA; COCAINE DERIVATIVE; DIHYDROERGOCRYPTINE; DOPAMINE TRANSPORTER; LEVODOPA; N (3 IODOPROPEN 2 YL) 2BETA CARBOXYMETHYL 3BETA 4 CHLOROPHENYLTROPANE; PRAMIPEXOLE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOPAMINERGIC NERVE CELL; FEMALE; FOLLOW UP; HUMAN; MALE; MONOTHERAPY; MULTICENTER STUDY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE BLIND PROCEDURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TIME; TREATMENT OUTCOME;

ADOLESCENT; AGED; CAUDATE NUCLEUS; DIHYDROERGOCRYPTINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEOSTRIATUM; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PUTAMEN; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 3843110191     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ahlskog JE (2003) Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 60: 381-389
2. Albin RL, Frey KA (2003) Initial agonist treatment of Parkinson disease: a critique. Neurology 60: 390-394
3. Battistin L, Bardin PG, Ferro-Milone F, Ravenna C, Toso V, Reboldi G (1999) Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study. Acta Neurol Scand 99: 36-42
4. Benzi G, Pastoris O, Villa RF (1988) Changes induced by aging and drug treatment on cerebral enzymatic antioxidant system. Neurochem Res 13: 467-478
5. Bergamasco B, Frattola L, Muratorio A, Piccoli F, Mailland F, Parnetti L (2000) Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol Scand 101: 372-380
6. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455
7. Bernocchi G, Gerzeli G, Scherini E, Vignola C (1993) Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Neuropathol (Berl) 85: 404-413
8. Bonuccelli U, D'Antonio P, D'Avino C, Piccini P, Muratorio A (1995) Dihydroergocryptine in the treatment of Parkinson's disease. J Neural Transm [Suppl] 45: 239-245
9. Brooks DJ (2000) Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm [Suppl] 60: 125-137
10. Brooks DJ (2003) Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 53 [Suppl] 3: S110-118; discussion S118-S119
11. Carvey PM, Pieri S, Ling ZD (1997) Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 104: 209-228
12. Cheng N, Maeda T, Kume T, Kaneko S, Kochiyama H, Akaike A, Goshima Y, Misu Y (1996) Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res 743: 278-283
13. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J (2001) Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 22: 721-725
14. Coppi G (1995) Neuroprotective activity of alpha-dihydroergocryptine in animal models. J Neural Transm [Suppl] 45: 307-318
15. Fahn S (1999) Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-DOPA. Arch Neurol 56: 529-535
16. Felten DL, Felten SY, Steece-Collier K, Date I, Clemens JA (1992) Age-related decline in the dopaminergic nigrostriatal system: the oxidative hypothesis and protective strategies. Ann Neurol 32 [Suppl]: S133-S136
17. Fiore L, Scapagnini U, Canonico PL (1987) Effect of dihydroergocryptine and dihydroergocristine on cyclic AMP accumulation and prolactin release in vitro: evidence for a dopaminomimetic action. Horm Res 25: 171-177
18. Frey KA, Koeppe RA, Kilbourn MR (2001) Imaging the vesicular monoamine transporter. Adv Neurol 86: 237-247
19. Gnanalingham KK, Robertson RG (1994) The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat - an autoradiographic study. Brain Res 640: 185-194
20. Hadjiconstantinou M, Wemlinger TA, Sylvia CP, Hubble JP, Neff NH (1993) Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J Neurochem 60: 2175-2180
21. Hastings TG, Zigmond MJ (1997) Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J Neural Transm [Suppl] 49: 103-110
22. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N (1999) Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838: 51-59
23. Ikawa K, Watanabe A, Kaneno S, Toni M (1993) Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol 250: 261-266
24. Kim HJ, Im JH, Yang SO, Moon DH, Ryu JS, Bong JK, Nam KP, Cheon JH, Lee MC, Lee HK (1997) Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 38: 1703-1711
25. Lang AE, Lees A (2002) DA agonists - ergot derivates: dihydroergocryptine (DHEC). Mov Disord 17: S72-S73
26. Le WD, Jankovic J (2001) Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 18: 389-396
27. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47: 493-503
28. Linke R, Gostomzyk J, Hahn K, Tatsch K (2000) [123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med 27: 1809-1812
29. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57: 2089-2094
30. McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24: 574-576
31. Meiergerd SM, Patterson TA, Schenk JO (1993) D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 61: 764-767
32. Minea D, Varga I, Falup-Pecurariu C, de Mey C, Retzow A, Althaus M (2001) Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease. Clin Neuropharmacol 24: 235-238
33. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58: 11-17
34. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64: 314-319
35. Neusch C, Bohme V, Riesland N, Althaus M, Moser A (2000) The dopamine D2 receptor agonist alpha-dihydroergocryptine modulates voltage-gated sodium channels in the rat caudate-putamen. J Neural Transm 107: 531-541
36. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, Rinne JO (2001) Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16: 608-615
37. Olanow CW, Jenner P, Brooks D (1998) Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44: S167-S174
38. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Jama 287: 1653-1661
39. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50: 743-755
40. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, Brucke T (2002) Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 17: 45-53
41. Poli M, Cocchi D, Mailland F, Masu AM, Landi G, Craveri A, Muller EE (1986) Prolactin lowering effect of dihydroergokryptine in rat and in man. J Endocrinol Invest 9: 31-36
42. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342: 1484-1491
43. Rascol O, Ferreira JJ, Thalamas C, Galitsky M, Montastruc JL (2001) Dopamine agonists. Their role in the management of Parkinson's disease. Adv Neurol 86: 301-309
44. Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K (2000) Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 57: 205-208
45. Sethy VH, Wu H, Oostveen JA, Hall ED (1997) Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res 754: 181-186
46. Tatsch K (2001) Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Commun 22: 819-827
47. Tatsch K (2002) Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Eur J Nucl Med Mol Imaging 29: 711-714
48. Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF (1997) Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 24: 415-421
49. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, Pupi A (2002) European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging 29: BP30-BP35
50. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10: 36-43
51. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54: 93-101
52. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC (2003) [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 74: 294-298
53. Wooten GF (2003) Agonists vs levodopa in PD: the thrilla of whitha. Neurology 60: 360-362
54. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62: 1034-1038